Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
heart failure
kidney function tests
renal insufficiency, chronic
sodium-glucose transporter 2 inhibitors
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
26 01 2021
26 01 2021
Historique:
pubmed:
13
10
2020
medline:
29
12
2021
entrez:
12
10
2020
Statut:
ppublish
Résumé
Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated with worse outcomes. We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to baseline kidney function, in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure). We also examined the effect of dapagliflozin on kidney function after randomization. Patients who have HFrEF with or without type 2 diabetes and an estimated glomerular filtration rate (eGFR) ≥30 mL·min Of 4742 patients with a baseline eGFR, 1926 (41%) had eGFR <60 mL·min Baseline kidney function did not modify the benefits of dapagliflozin on morbidity and mortality in HFrEF, and dapagliflozin slowed the rate of decline in eGFR, including in patients without diabetes. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
Sections du résumé
BACKGROUND
Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated with worse outcomes. We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to baseline kidney function, in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure). We also examined the effect of dapagliflozin on kidney function after randomization.
METHODS
Patients who have HFrEF with or without type 2 diabetes and an estimated glomerular filtration rate (eGFR) ≥30 mL·min
RESULTS
Of 4742 patients with a baseline eGFR, 1926 (41%) had eGFR <60 mL·min
CONCLUSIONS
Baseline kidney function did not modify the benefits of dapagliflozin on morbidity and mortality in HFrEF, and dapagliflozin slowed the rate of decline in eGFR, including in patients without diabetes. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
Identifiants
pubmed: 33040613
doi: 10.1161/CIRCULATIONAHA.120.050391
pmc: PMC7834909
doi:
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
dapagliflozin
1ULL0QJ8UC
Banques de données
ClinicalTrials.gov
['NCT03036124']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
298-309Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK045735
Pays : United States
Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Références
Eur J Heart Fail. 2019 May;21(5):665-675
pubmed: 30895697
J Am Coll Cardiol. 2000 Apr;35(5):1245-55
pubmed: 10758967
JAMA. 2020 Apr 14;323(14):1353-1368
pubmed: 32219386
Circulation. 2018 Oct 9;138(15):1505-1514
pubmed: 30002098
Eur J Heart Fail. 2019 Nov;21(11):1402-1411
pubmed: 31309699
Stat Med. 2004 Aug 30;23(16):2509-25
pubmed: 15287081
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
J Am Coll Cardiol. 2020 Feb 4;75(4):422-434
pubmed: 32000955
Circulation. 2020 Jan 14;141(2):90-99
pubmed: 31736335
Diabetologia. 2020 Jun;63(6):1128-1140
pubmed: 32236732
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Eur Heart J. 2014 Feb;35(7):455-69
pubmed: 24164864
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
Kidney Int. 2020 Apr;97(4):631-635
pubmed: 32200854
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Circ Heart Fail. 2017 Feb;10(2):
pubmed: 28209765
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593
pubmed: 32559474
Stat Med. 2019 Sep 30;38(22):4218-4239
pubmed: 31338848
J Am Coll Cardiol. 2019 Dec 10;74(23):2893-2904
pubmed: 31806133
Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282
pubmed: 32030417
JACC Heart Fail. 2018 Jun;6(6):489-498
pubmed: 29655829
J Card Fail. 2017 Jan;23(1):2-9
pubmed: 27638233
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
J Am Coll Cardiol. 2014 Mar 11;63(9):853-71
pubmed: 24334210
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Eur J Heart Fail. 2016 Dec;18(12):1508-1517
pubmed: 27427441
Circulation. 2021 Feb 2;143(5):438-448
pubmed: 33186054
Diabetes Obes Metab. 2020 Apr;22 Suppl 1:55-68
pubmed: 32267075
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522
pubmed: 31996025